Acorda Therapeutics Inc (NASDAQ:ACOR) saw unusually large options trading activity on Wednesday. Stock traders acquired 1,194 put options on the stock. This represents an increase of 1,272% compared to the average volume of 87 put options.

Acorda Therapeutics (NASDAQ:ACOR) opened at $25.85 on Monday. Acorda Therapeutics has a 52 week low of $13.60 and a 52 week high of $33.00. The company has a market cap of $1,208.41, a PE ratio of -21.36 and a beta of 1.58. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The company had revenue of $141.07 million during the quarter, compared to analyst estimates of $150.64 million. During the same quarter last year, the company posted ($0.04) EPS. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. equities analysts forecast that Acorda Therapeutics will post -0.02 earnings per share for the current year.

In other news, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the transaction, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACOR. State Street Corp boosted its holdings in Acorda Therapeutics by 52.4% in the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after purchasing an additional 851,290 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Acorda Therapeutics by 29.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after purchasing an additional 541,418 shares during the period. RA Capital Management LLC boosted its holdings in Acorda Therapeutics by 83.8% in the 2nd quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock valued at $17,735,000 after purchasing an additional 410,431 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Acorda Therapeutics by 306.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after purchasing an additional 403,467 shares during the period. Finally, Northern Trust Corp boosted its holdings in Acorda Therapeutics by 65.2% in the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock valued at $17,690,000 after purchasing an additional 354,304 shares during the period.

Several research firms have recently weighed in on ACOR. Goldman Sachs Group restated a “sell” rating and set a $20.00 price objective on shares of Acorda Therapeutics in a research note on Friday, October 6th. Raymond James Financial lowered shares of Acorda Therapeutics from a “market perform” rating to an “underperform” rating and boosted their price objective for the stock from $7.00 to $13.00 in a research note on Thursday, November 16th. Zacks Investment Research lowered shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. JPMorgan Chase & Co. set a $24.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a research note on Tuesday, October 31st. Finally, Oppenheimer started coverage on shares of Acorda Therapeutics in a research note on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Acorda Therapeutics has a consensus rating of “Hold” and a consensus target price of $21.35.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/14/investors-buy-high-volume-of-put-options-on-acorda-therapeutics-acor.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.